Sample | GWAS sample size (N) | Microarray used | Primary outcome measure | Response phenotype definition | SNPs reaching suggestive levels of significance (nearest gene) | |
---|---|---|---|---|---|---|
STAR*D [5] | 1,948 | Affymetrix 500K/5.0 human SNP arrays | QID-SR | Response: >50% reduction in score | rs6966038 (UBE3C), rs6127921 (BMP7), rs809736 (RORA) | |
 |  |  |  | Remission: score <5 |  |  |
MARS [9] | 339 (two replication samples, N=361 and N=831) | Sentrix Human-1 and HumanHap300 BeadChip | HAM-D | Early partial response: >25% reduction in score after 2 weeks of treatment | rs6989467 (CDH17)a, rs1502174 (EPHB1) | |
 |  |  |  | Response: >50% reduction in score |  |  |
 |  |  |  | Remission: score <10 |  |  |
GENDEP [13] | 706 | Illumina 610 array | MADRS | Percentage change from baseline to week 12 | Whole-sample analysis | rs2136093, rs6701608 and rs2136094 (intergenic, on chromosome 1)rs16920624, rs11598854 and rs7081156 (intergenic, on chromosome 10) |
 |  |  |  |  | Escitalopram-specific analysis | rs1126757 (IL11) |
 |  |  |  |  | Nortriptyline-specific analysis | rs2500535 (UST) |
 |  |  |  |  | Gene-by-drug analysis | rs2500535 (UST) |